• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Waterdrop Inc. Announces First Quarter 2024 Unaudited Financial Results

    6/5/24 6:00:00 AM ET
    $WDH
    Specialty Insurers
    Finance
    Get the next $WDH alert in real time by email

    BEIJING, June 5, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three months ended March 31, 2024.

    Financial and Operational Highlights for the First Quarter of 2024

    • Consecutive profitability and positive operating cash flow: In the first quarter of 2024, net profit attributable to our ordinary shareholders reached RMB80.6 million, representing a quarter-over-quarter growth of 36.5%. As of March 31, 2024, our cash and cash equivalents and short-term investments balance amounted to RMB3,484.4 million (US$482.6 million). We continued to generate positive operating cash flow during the first quarter of 2024.
    • Robust business performance: For the first quarter of 2024, the first-year premiums ("FYP") generated through our insurance business amounted to RMB1,754.5 million (US$243.0 million), representing an increase of 3.7% year over year. Net operating revenue was RMB704.7 million (US$97.6 million), representing an increase of 16.3% year over year.
    • Improving FYP share from life insurance products: The contribution of FYP generated from long-term insurance products to overall FYP has further increased. In addition, in the first quarter of 2024, the FYP generated from life insurance products increased 9.9 percentage points to 56.4% of overall long-term insurance products from 46.5% for the same period of 2023.
    • Broadening crowdfunding coverage: As of March 31, 2024, around 456 million people cumulatively had donated an aggregate of approximately RMB63.8 billion to over 3.17 million patients through Waterdrop Medical Crowdfunding.
    • Digital clinical trial services in good progress: As of March 31, 2024, the Company had cumulatively enrolled nearly 7,800 patients into over 960 clinical trial programs through E-Find Platform.

    Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "We are thrilled to kick off 2024 with solid first quarter financial results. The quarterly net profit attributable to our ordinary shareholders reached RMB80.6 million, representing a quarter-over-quarter growth of 36.5%. We are also pleased to have maintained profitability for nine consecutive quarters.

    Waterdrop Insurance Marketplace has continually improved online traffic conversion capabilities and efficiency. We have been leveraging various content distribution platforms and optimizing our product offerings accordingly. Our capability in tailoring various products to meet user needs continues to improve. Targeting a market segment, we have successfully upgraded one of our star products "Jiehaoyun" to version 2.0, which gained top recognition on various platforms. The FYP generated through our insurance business increased by 15.0% sequentially. Meanwhile, we have effectively sustained the policy renewal rate at above 95%.

    Regarding Waterdrop Medical Crowdfunding, we ensured stringent oversight over the transparency of fundraising activities on our platform and strengthened our risk management measures. For instance, before manual verification, we integrated algorithm recognition to identify false or fake medical documents and mitigate related risks effectively.

    In this quarter, our healthcare-related business continued its momentum, bringing the number of collaborating pharmaceutical companies and contract research organizations (collectively, "CROs") to 179. In addition, we enrolled over 800 patients and started providing services to 88 new programs in the first quarter of 2024. We accelerated the implementation of our digital capabilities in clinical trial solution and multichannel marketing to serve a broader client base.

    Looking ahead, we are committed to patiently building core technology competitiveness for the Company, supporting the long-term strategic execution to maintain stable profitability. Guided by our mission and values, we will continuously explore more customized, cost-effective products and services, while expanding our business boundaries."

    Financial Results for the First Quarter of 2024

    Operating revenue, net

    Net operating revenue for the first quarter of 2024 increased by 16.3% year over year to RMB704.7 million (US$97.6 million) from RMB606.2 million for the same period of 2023. On a quarter-over-quarter basis, net operating revenue increased by 6.9%. We started to consolidate the financial results of Shenzhen Cunzhen Qiushi Technology Co., Ltd. and its subsidiaries (collectively, "Cunzhen Qiushi", also known as "Shenlanbao") in the third quarter of 2023. Net operating revenue generated by Shenlanbao for the first quarter of 2024 was RMB59.7 million (US$8.3 million).

    • Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to RMB606.8 million (US$84.0 million) in the first quarter of 2024, representing an increase of 13.1% year over year from RMB536.3 million for the first quarter of 2023, which was mainly due to the increase in insurance brokerage income. On a quarter-over-quarter basis, insurance-related income increased by 3.2%.



    • Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the first quarter of 2024, we generated RMB67.4 million (US$9.3 million) in service fees, representing an increase of 60.3% year over year from RMB42.0 million for the first quarter of 2023. On a quarter-over-quarter basis, crowdfunding service fees increased by 68.3%.



    • We are expanding the healthcare-related services, including digital clinical trial solution and digital multichannel marketing solution. Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. Digital multichannel marketing solution income is derived from life science and healthcare companies. Focusing on the needs of our customers, we provide comprehensive digital marketing solutions around the whole life cycle of products through integrated services such as patient screening, medication management, doctor-patient services, innovative payment methods, and channel marketing. For the first quarter of 2024, our healthcare-related income amounted to RMB25.3 million (US$3.5 million), representing an increase of 7.3% from RMB23.6 million in the same period of 2023. On a quarter-over-quarter basis, healthcare-related income decreased by 8.3%.

    Operating costs and expenses

    Operating costs and expenses increased by 10.5% year over year to RMB658.3 million (US$91.2 million) for the first quarter of 2024. On a quarter-over-quarter basis, operating costs and expenses increased by 4.0%. Operating costs and expenses from Shenlanbao was RMB63.1 million (US$8.7 million).

    • Operating costs increased by 33.6% year over year to RMB331.2 million (US$45.9 million) for the first quarter of 2024, as compared with RMB248.0 million for the first quarter of 2023, which was primarily driven by (i) an increase of RMB13.8 million in personnel costs mainly due to the consolidation of the financial results of Shenlanbao which incurred personnel costs of RMB17.2 million, and (ii) an increase of RMB66.0 million in costs of referral and service fees. On a quarter-over-quarter basis, operating costs increased by 9.6% from RMB302.1 million, primarily due to an increase of RMB29.7 million in costs of referral and service fees. 



    • Sales and marketing expenses increased by 5.0% year over year to RMB182.1 million (US$25.2 million) for the first quarter of 2024, as compared with RMB173.4 million for the same quarter of 2023. The increase was primarily due to (i) the consolidation of the financial results of Shenlanbao which incurred sales and marketing expenses of RMB34.2 million, (ii) an increase of RMB6.4 million in outsourced sales and marketing service fees to third parties, (iii) an increase of RMB4.1 million in marketing expenses to third-party traffic channels, partially offset by (iv) a decrease of RMB37.0 million in personnel costs and share-based compensation expenses. On a quarter-over-quarter basis, sales and marketing expenses increased by 4.2% from RMB174.8 million, primarily due to (i) an increase of RMB18.3 million in marketing expenses to third-party traffic channels, (ii) an increase of RMB5.8 million in outsourced sales and marketing service fees to third parties, partially offset by (iii) a decrease of RMB17.3 million in sales and marketing personnel costs and share-based compensation expenses.



    • General and administrative expenses decreased by 7.1% year over year to RMB89.0 million (US$12.3 million) for the first quarter of 2024, compared with RMB95.8 million for the same quarter of 2023. The year-over-year variance was due to (i) a decrease of RMB12.7 million in personnel costs and share-based compensation expenses, and partially offset by (ii) an increase of RMB8.6 million allowance for doubtful accounts. On a quarter-over-quarter basis, general and administrative expenses decreased by 7.3% from RMB96.0 million, due to (i) a decrease of RMB13.5 million allowance for doubtful accounts, partially offset by (ii) an increase of RMB4.4 million in professional service fees, and (iii) an increase of RMB3.1 million in personnel costs and share-based compensation expenses.



    • Research and development expenses decreased by 28.8% year over year to RMB56.0 million (US$7.8 million) for the first quarter of 2024, compared with RMB78.7 million for the same period of 2023. The decrease was primarily due to a decrease of RMB26.3 million in personnel costs and share-based compensation expenses, partially offset by the consolidation of the financial results of Shenlanbao. On a quarter-over-quarter basis, research and development expenses decreased by 6.4% from RMB59.8 million, which was mainly due to a decrease of RMB3.9 million in research and development personnel costs and share-based compensation expenses.

    Operating profit for the first quarter of 2024 was RMB46.4 million (US$6.4 million), as compared with RMB10.3 million for the first quarter of 2023 and RMB26.6 million for the fourth quarter of 2023.

    Interest income for the first quarter of 2024 was RMB39.8 million (US$5.5 million), as compared with RMB30.9 million for the first quarter of 2023 and RMB34.7 million for the fourth quarter of 2023. The increase was primarily due to the increase in our short-term and long-term investments and interest rate.

    Income tax expense for the first quarter of 2024 was RMB8.6 million (US$1.2 million), as compared with an income tax benefit of RMB2.6 million for the first quarter of 2023 and an income tax expense of RMB15.2 million for the fourth quarter of 2023.

    Net profit attributable to the Company's ordinary shareholders for the first quarter of 2024 was RMB80.6 million (US$11.2 million), as compared with RMB49.7 million for the same period of 2023, and RMB59.1 million for the fourth quarter of 2023.

    Adjusted net profit attributable to the Company's ordinary shareholders for the first quarter of 2024 was RMB98.4 million (US$13.6 million), as compared with RMB96.4 million for the same period of 2023, and RMB74.7 million for the fourth quarter of 2023. 

    Cash and cash equivalents and short-term investments

    As of March 31, 2024, the Company had combined cash and cash equivalents and short-term investments of RMB3,484.4 million (US$482.6 million), as compared with RMB3,393.4 million as of December 31, 2023.

    Share Repurchase Programs

    Pursuant to the share repurchase programs launched in September 2021, September 2022 and September 2023, respectively, we had cumulatively repurchased approximately 45.5 million ADSs from the open market with cash for a total consideration of approximately US$95.9 million as of May 31, 2024.

    Supplemental Information

    Starting from the second quarter of 2023, our chief operating decision maker starts to manage the business by three operating segments and assess the performance and allocate resources under the new operating segment structure.

    Therefore, we organize and report our business in three operating segments:

    • Insurance, which mainly includes Waterdrop Insurance Marketplace, Shenlanbao Insurance Marketplace and technical support service;
    • Crowdfunding, which mainly includes Waterdrop Medical Crowdfunding; and
    • Others, which mainly include Digital Clinical Trial Solution and other new initiatives.

    As a result, we have updated our segments reporting information to reflect the new operating and reporting structure.

    Comparative figures were retrospectively adjusted to conform to this presentation.





    For the Three Months Ended





    March 31, 2023



    December 31,

    202
    3



    March 31, 2024





    RMB



    RMB



    RMB



    USD





    (All amounts in thousands)

    Operating revenue, net

















    Insurance*



    536,343



    587,866



    606,777



    84,038

    Crowdfunding



    42,022



    40,013



    67,350



    9,328

    Others



    27,800



    31,485



    30,573



    4,234

    Total consolidated operating

        revenue, net



    606,165



    659,364



    704,700



    97,600

    Operating profit/(loss)

















    Insurance*



    154,955



    128,223



    129,163



    17,889

    Crowdfunding



    (61,134)



    (51,718)



    (32,237)



    (4,465)

    Others



    (36,567)



    (27,078)



    (31,432)



    (4,354)

    Total segment operating

        profit



    57,254



    49,427



    65,494



    9,070

    Unallocated item**



    (46,926)



    (22,788)



    (19,130)



    (2,649)

    Total consolidated operating

        profit



    10,328



    26,639



    46,364



    6,421

    Total other income



    36,771



    44,463



    42,781



    5,926

    Profit before income tax



    47,099



    71,102



    89,145



    12,347

    Income tax benefit/(expense)



    2,626



    (15,164)



    (8,588)



    (1,189)

    Net profit



    49,725



    55,938



    80,557



    11,158



    * The Company started to consolidate the financial results of Shenlanbao since July 4, 2023 and reported the results of 

      Shenlanbao under the Insurance segment.

    ** The share-based compensation represents an unallocated item in the segment information because our management does

        not consider this as part of the segment operating performance measure.

    Exchange Rate

    This announcement contains translations of certain RMB amounts into U.S. dollars ("USD" or "US$") at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to USD were made at the rate of RMB7.2203 to US$1.00, the noon buying rate in effect on March 29, 2024 in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or USD amounts referred could be converted into USD or RMB, as the case may be, at any particular rate or at all. For analytical presentation, all percentages are calculated using the numbers presented in the financial statements contained in this earnings release.

    Non-GAAP Financial Measure

    The Company uses non-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation expense attributable to our ordinary shareholders and foreign currency exchange gain or losses. Such adjustments have no impact on income tax.

    The non-GAAP financial measure is not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measure has limitations as analytical tools and when assessing the Company's operating performance, investors should not consider it in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Investors are encouraged to review the Company's historical non-GAAP financial measure to the most directly comparable GAAP measure. Adjusted net profit attributable to our ordinary shareholders presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measure differently, limiting its usefulness as a comparative measure to our data.

    The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable U.S. GAAP performance measure, all of which should be considered when evaluating the Company's performance.

    For more information on the non-GAAP financial measure, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    Safe Harbor Statement

    This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to" and similar statements. Among other things, quotations in this announcement, contain forward-looking statements. Waterdrop may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Waterdrop's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Waterdrop's mission, goals and strategies; Waterdrop's future business development, financial condition and results of operations; the expected growth of the insurance, medical crowdfunding and healthcare industry in China; Waterdrop's expectations regarding demand for and market acceptance of our products and services; Waterdrop's expectations regarding its relationships with consumers, insurance carriers and other partners; competition in the industry and relevant government policies and regulations relating to insurance, medical crowdfunding and healthcare industry. Further information regarding these and other risks is included in Waterdrop's filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    Conference Call Information 

    Waterdrop's management team will hold a conference call on June 5, 2024 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

    International:

    1-412-317-6061

    United States Toll Free:

    1-888-317-6003

    Hong Kong Toll Free:

    800-963976

    Hong Kong:

    852-58081995

    Mainland China:

    4001-206115

    Chinese Line (Mandarin) Entry Number:

    8399398

    English Interpretation Line (Listen-only Mode) Entry Number:

    0418783

    Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

    Telephone replays will be accessible two hours after the conclusion of the conference call through June 12, 2024 by dialing the following numbers:

    United States Toll Free:

    1-877-344-7529

    International:

    1-412-317-0088

    Chinese Line Access Code:

    2937700

    English Interpretation Line Access Code:

    1729095

    A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/.

    About Waterdrop Inc.

    Waterdrop Inc. (NYSE:WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

    For investor inquiries, please contact

    Waterdrop Inc.

    [email protected]

     

    WATERDROP INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (All amounts in thousands, unless otherwise noted)







    As of





    December 31, 2023



    March 31, 2024





    RMB



    RMB



    USD















    Assets













    Current assets













    Cash and cash equivalents



    396,905



    321,780



    44,566

    Restricted cash



    577,121



    404,201



    55,981

    Short-term investments



    2,996,527



    3,162,661



    438,023

    Accounts receivable, net



    693,110



    726,815



    100,663

    Current contract assets



    572,871



    594,282



    82,307

    Amount due from related parties



    65



    163



    23

    Prepaid expense and other assets



    189,846



    163,368



    22,626

    Total current assets



    5,426,445



    5,373,270



    744,189

    Non-current assets













    Non-current contract assets



    134,383



    141,542



    19,603

    Property, equipment and software, net



    33,878



    32,950



    4,564

    Intangible assets, net



    177,407



    173,667



    24,053

    Long-term investments



    211,758



    217,397



    30,109

    Right of use assets, net



    59,851



    68,512



    9,489

    Deferred tax assets



    24,190



    25,042



    3,468

    Goodwill



    80,751



    80,751



    11,184

    Total non-current assets



    722,218



    739,861



    102,470

    Total assets



    6,148,663



    6,113,131



    846,659















    Liabilities, Mezzanine Equity and Shareholders' Equity













    Current liabilities













    Amount due to related parties



    9,509



    12,794



    1,772

    Insurance premium payables



    591,953



    405,672



    56,185

    Accrued expenses and other current liabilities



    597,684



    790,723



    109,514

    Short-term loans



    137,557



    75,173



    10,411

    Current lease liabilities



    32,908



    34,320



    4,753

    Total current liabilities



    1,369,611



    1,318,682



    182,635

    Non-current liabilities













    Non-current lease liabilities



    27,293



    33,465



    4,635

    Deferred tax liabilities



    73,305



    82,380



    11,409

    Total non-current liabilities



    100,598



    115,845



    16,044

    Total liabilities



    1,470,209



    1,434,527



    198,679















    Mezzanine Equity













    Redeemable non-controlling interests



    92,760



    92,685



    12,837















    Shareholders' equity













    Class A ordinary shares



    112



    112



    16

    Class B ordinary shares



    27



    27



    4

    Treasury stock



    (12)



    (13)



    (2)

    Additional paid-in capital



    7,003,423



    6,897,876



    955,345

    Accumulated other comprehensive income



    144,107



    169,250



    23,441

    Accumulated deficit



    (2,561,963)



    (2,481,333)



    (343,661)

    Total shareholders' equity



    4,585,694



    4,585,919



    635,143

    Total liabilities, mezzanine equity and shareholders' equity



    6,148,663



    6,113,131



    846,659

     

    WATERDROP INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

    (All amounts in thousands, except for share and per share data, or otherwise noted)







    For the Three Months Ended





    March 31, 2023



    December 31, 2023



    March 31, 2024





    RMB



    RMB



    RMB



    USD



















    Operating revenue, net



    606,165



    659,364



    704,700



    97,600

    Operating costs and expenses(i)

















    Operating costs



    (247,983)



    (302,143)



    (331,243)



    (45,877)

    Sales and marketing expenses



    (173,401)



    (174,817)



    (182,146)



    (25,227)

    General and administrative expenses



    (95,798)



    (95,959)



    (88,961)



    (12,321)

    Research and development expenses



    (78,655)



    (59,806)



    (55,986)



    (7,754)

    Total operating costs and expenses



    (595,837)



    (632,725)



    (658,336)



    (91,179)

    Operating profit



    10,328



    26,639



    46,364



    6,421

    Other income

















    Interest income



    30,876



    34,659



    39,804



    5,513

    Foreign currency exchange gain



    282



    6,956



    1,514



    210

    Others, net



    5,613



    2,848



    1,463



    203

    Profit before income tax



    47,099



    71,102



    89,145



    12,347

    Income tax benefit/(expense)



    2,626



    (15,164)



    (8,588)



    (1,189)

    Net profit



    49,725



    55,938



    80,557



    11,158

    Net loss attributable to mezzanine equity classified as non-

         controlling interests shareholders



     

    -



     

    (3,119)



     

    (75)



     

    (10)

    Net profit attributable to ordinary shareholders



    49,725



    59,057



    80,632



    11,168

    Other comprehensive income/(loss):

















    Foreign currency translation adjustment, net of tax



    3,386



    (39,390)



    25,143



    3,482

    Unrealized gain on available for sale investments, net of tax



    1,957



    -



    -



    -

    Total comprehensive income



    55,068



    16,548



    105,700



    14,640

    Total comprehensive loss attributable to mezzanine equity classified

        as non-controlling interests shareholders



     

    -



     

    (3,119)



     

    (75)



     

    (10)

    Total comprehensive income attributable to ordinary shareholders



    55,068



    19,667



    105,775



    14,650

    Weighted average number of ordinary shares used in computing

    net profit per share





    Basic



    3,866,785,745



    3,698,466,876



    3,696,619,172



    3,696,619,172

    Diluted



    4,027,428,601



    3,762,270,456



    3,756,462,107



    3,756,462,107

    Net profit per share attributable to ordinary shareholders

















    Basic



    0.01



    0.02



    0.02



    0.00

    Diluted



    0.01



    0.02



    0.02



    0.00



















    (i) Share-based compensation expenses are included in the operating costs and expenses as follows. 























    For the Three Months Ended





    March 31, 2023



    December 31, 2023



    March 31, 2024





    RMB



    RMB



    RMB



    USD



















    Sales and marketing expenses



    (16,529)



    (1,991)



    (1,820)



    (252)

    General and administrative expenses



    (26,460)



    (18,693)



    (14,327)



    (1,984)

    Research and development expenses



    (3,937)



    (2,104)



    (2,983)



    (413)

    Total



    (46,926)



    (22,788)



    (19,130)



    (2,649)

     

    WATERDROP INC.

    RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

    (All amounts in thousands, unless otherwise noted)







    For the Three Months Ended





    March 31, 2023



    December 31, 2023



    March 31, 2024





    RMB



    RMB



    RMB



    USD



















    Net profit attributable to the Company's ordinary shareholders



    49,725



    59,057



    80,632



    11,168

    Add:

















    Share-based compensation expense attributable to the Company's

         ordinary shareholders



    46,926



    22,556



    19,260



    2,667

    Foreign currency exchange gain



    (282)



    (6,956)



    (1,514)



    (210)

    Adjusted net profit attributable to the Company's ordinary

        shareholders



    96,369



    74,657



    98,378



    13,625

     

    Cision View original content:https://www.prnewswire.com/news-releases/waterdrop-inc-announces-first-quarter-2024-unaudited-financial-results-302164606.html

    SOURCE Waterdrop Inc.

    Get the next $WDH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WDH

    DatePrice TargetRatingAnalyst
    9/16/2022$2.00 → $2.10Equal-Weight → Overweight
    Morgan Stanley
    3/25/2022$5.00 → $2.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $WDH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Waterdrop Inc. Releases 2024 Annual Report: AI-Enabled Efficiencies Drive Business Growth

      BEIJING, April 30, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the filing of its annual report for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (SEC). For the year, the Company reported net revenue of RMB 2.772 billion and net profit attributable to shareholders of RMB 368 million, representing a 119.8% year-on-year increase. This achievement extends the company's streak of profitability to 12 consecutive quarters. As of the end of February 2025, Waterdrop had repurchased approximately 5

      4/30/25 3:35:00 AM ET
      $WDH
      Specialty Insurers
      Finance
    • WATERDROP FILES ANNUAL REPORT ON FORM 20-F FOR FISCAL YEAR 2024

      BEIJING, April 25, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on April 25, 2025. The annual report can be accessed on the Company's investor relations website at https://ir.waterdrop-inc.com as well as the SEC's website at http://www.sec.gov.  The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its share

      4/25/25 6:52:00 AM ET
      $WDH
      Specialty Insurers
      Finance
    • Goldman Sachs Maintains 'Buy' Rating for Waterdrop with Price Target of US$1.80

      BEIJING, March 19, 2025 /PRNewswire/ -- Following the release of Waterdrop Inc.'s (WDH) fourth-quarter and full-year 2024 financial results, Goldman Sachs' latest research report maintains a "Buy" rating for Waterdrop and sets a 12-month price target of US$1.80 per ADS. According to Goldman Sachs' report, Waterdrop achieved a higher-than-expected net profit attributable to shareholders of 368 million yuan (approx. US$51 million) for the full year of 2024, representing a year-on-year increase of 119.8%. In the fourth quarter of 2024, the first-year premium (FYP) for the insurance business reached approximately 1.9 billion yuan (approx. US$263 million), up 24.5% year-on-year, primarily driven

      3/19/25 8:46:00 AM ET
      $WDH
      Specialty Insurers
      Finance

    $WDH
    Leadership Updates

    Live Leadership Updates

    See more
    • Waterdrop Q4 and FY2024 Financial Results: Annual Net profit rises 119.8% YoY, and declared a cash dividend

      BEIJING, March 12, 2025 /PRNewswire/ -- On March 12, 2025, Waterdrop Inc. (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the fourth quarter and Fiscal Year ended December 31, 2024. During the fourth quarter, Waterdrop reported net operating revenue of RMB 686.8 million. Net profit attributable to ordinary shareholders totaled RMB 99.6 million, up 68.5% from the same quarter of previous year, sustaining profitability for the twelfth consecutive quarter. Operating expenses, including sales and marketing expenses, general and administrative expenses, research and development ex

      3/12/25 7:18:00 AM ET
      $WDH
      Specialty Insurers
      Finance
    • Waterdrop Inc. Announces Appointment of New Independent Director

      BEIJING, March 12, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Mr. Chen Lin as an independent director and a member of the audit committee of the Company's board of directors (the "Board"), replacing Mr. Ning Zhu, effective March 11, 2025. Mr. Ning Zhu has tendered his resignation as an independent director and a member of the audit committee of the Board due to personal reasons. The resignation of Mr. Zhu was not due to any dispute or disagreement with the Company. Mr. Chen Lin has served at various positions at Th

      3/12/25 6:17:54 AM ET
      $WDH
      Specialty Insurers
      Finance
    • Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

      The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced the successful completion of a $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Eme

      11/28/24 8:06:00 AM ET
      $BZ
      $HUYA
      $LI
      $PDD
      Computer Software: Programming Data Processing
      Technology
      Auto Manufacturing
      Consumer Discretionary

    $WDH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Waterdrop Inc. (Amendment)

      SC 13G/A - Waterdrop Inc. (0001823986) (Subject)

      2/13/24 6:10:20 AM ET
      $WDH
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by Waterdrop Inc. (Amendment)

      SC 13G/A - Waterdrop Inc. (0001823986) (Subject)

      2/9/24 4:15:26 PM ET
      $WDH
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by Waterdrop Inc. (Amendment)

      SC 13G/A - Waterdrop Inc. (0001823986) (Subject)

      2/9/24 6:02:43 AM ET
      $WDH
      Specialty Insurers
      Finance

    $WDH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Waterdrop upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Waterdrop from Equal-Weight to Overweight and set a new price target of $2.10 from $2.00 previously

      9/16/22 7:36:47 AM ET
      $WDH
      Specialty Insurers
      Finance
    • Waterdrop downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Waterdrop from Overweight to Equal-Weight and set a new price target of $2.00 from $5.00 previously

      3/25/22 9:17:38 AM ET
      $WDH
      Specialty Insurers
      Finance

    $WDH
    SEC Filings

    See more
    • SEC Form 20-F filed by Waterdrop Inc.

      20-F - Waterdrop Inc. (0001823986) (Filer)

      4/25/25 6:06:03 AM ET
      $WDH
      Specialty Insurers
      Finance
    • SEC Form 6-K filed by Waterdrop Inc.

      6-K - Waterdrop Inc. (0001823986) (Filer)

      3/12/25 9:17:21 AM ET
      $WDH
      Specialty Insurers
      Finance
    • SEC Form 6-K filed by Waterdrop Inc.

      6-K - Waterdrop Inc. (0001823986) (Filer)

      12/11/24 8:31:29 AM ET
      $WDH
      Specialty Insurers
      Finance

    $WDH
    Financials

    Live finance-specific insights

    See more
    • Goldman Sachs Maintains 'Buy' Rating for Waterdrop with Price Target of US$1.80

      BEIJING, March 19, 2025 /PRNewswire/ -- Following the release of Waterdrop Inc.'s (WDH) fourth-quarter and full-year 2024 financial results, Goldman Sachs' latest research report maintains a "Buy" rating for Waterdrop and sets a 12-month price target of US$1.80 per ADS. According to Goldman Sachs' report, Waterdrop achieved a higher-than-expected net profit attributable to shareholders of 368 million yuan (approx. US$51 million) for the full year of 2024, representing a year-on-year increase of 119.8%. In the fourth quarter of 2024, the first-year premium (FYP) for the insurance business reached approximately 1.9 billion yuan (approx. US$263 million), up 24.5% year-on-year, primarily driven

      3/19/25 8:46:00 AM ET
      $WDH
      Specialty Insurers
      Finance
    • Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results and a Cash Dividend

      BEIJING, March 12, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE:WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2024 and a cash dividend. Financial and Operational Highlights for the Fourth Quarter of 2024 Marked improvement in profitability and healthy liquidity: In the fourth quarter of 2024, net profit attributable to our ordinary shareholders reached RMB99.6 million (US$13.6 million), representing a year-over-year growth of 68.7%. We continued to generate positive operating cash flow during t

      3/12/25 6:17:57 AM ET
      $WDH
      Specialty Insurers
      Finance
    • Waterdrop Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 12, 2025

      BEIJING, Feb. 26, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before U.S. markets open on Wednesday, March 12, 2025. Waterdrop's management team will hold a conference call on March 12, 2025 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows: International: 1-412-317-6061 United States Toll Free: 1

      2/26/25 3:30:00 AM ET
      $WDH
      Specialty Insurers
      Finance